137 related articles for article (PubMed ID: 37952322)
1. Tracking the EMT-like phenotype switching during targeted therapy in melanoma by analyzing extracellular vesicle phenotypes.
Zhou Q; Wang J; Zhang Z; Wuethrich A; Lobb RJ; Trau M
Biosens Bioelectron; 2024 Jan; 244():115819. PubMed ID: 37952322
[TBL] [Abstract][Full Text] [Related]
2. The transcription cofactor c-JUN mediates phenotype switching and BRAF inhibitor resistance in melanoma.
Ramsdale R; Jorissen RN; Li FZ; Al-Obaidi S; Ward T; Sheppard KE; Bukczynska PE; Young RJ; Boyle SE; Shackleton M; Bollag G; Long GV; Tulchinsky E; Rizos H; Pearson RB; McArthur GA; Dhillon AS; Ferrao PT
Sci Signal; 2015 Aug; 8(390):ra82. PubMed ID: 26286024
[TBL] [Abstract][Full Text] [Related]
3. Tracking extracellular vesicle phenotypic changes enables treatment monitoring in melanoma.
Wang J; Wuethrich A; Sina AA; Lane RE; Lin LL; Wang Y; Cebon J; Behren A; Trau M
Sci Adv; 2020 Feb; 6(9):eaax3223. PubMed ID: 32133394
[TBL] [Abstract][Full Text] [Related]
4. Combinatorial Treatment with PARP and MAPK Inhibitors Overcomes Phenotype Switch-Driven Drug Resistance in Advanced Melanoma.
Ferretti LP; Böhi F; Leslie Pedrioli DM; Cheng PF; Ferrari E; Baumgaertner P; Alvarado-Diaz A; Sella F; Cereghetti A; Turko P; Wright RH; De Bock K; Speiser DE; Ferrari R; Levesque MP; Hottiger MO
Cancer Res; 2023 Dec; 83(23):3974-3988. PubMed ID: 37729428
[TBL] [Abstract][Full Text] [Related]
5. ZEB1-mediated melanoma cell plasticity enhances resistance to MAPK inhibitors.
Richard G; Dalle S; Monet MA; Ligier M; Boespflug A; Pommier RM; de la Fouchardière A; Perier-Muzet M; Depaepe L; Barnault R; Tondeur G; Ansieau S; Thomas E; Bertolotto C; Ballotti R; Mourah S; Battistella M; Lebbé C; Thomas L; Puisieux A; Caramel J
EMBO Mol Med; 2016 Oct; 8(10):1143-1161. PubMed ID: 27596438
[TBL] [Abstract][Full Text] [Related]
6. Microfluidic chip for rapid and selective isolation of tumor-derived extracellular vesicles for early diagnosis and metastatic risk evaluation of breast cancer.
Gwak H; Park S; Kim J; Lee JD; Kim IS; Kim SI; Hyun KA; Jung HI
Biosens Bioelectron; 2021 Nov; 192():113495. PubMed ID: 34273737
[TBL] [Abstract][Full Text] [Related]
7. NK-cell Editing Mediates Epithelial-to-Mesenchymal Transition via Phenotypic and Proteomic Changes in Melanoma Cell Lines.
Huergo-Zapico L; Parodi M; Cantoni C; Lavarello C; Fernández-Martínez JL; Petretto A; DeAndrés-Galiana EJ; Balsamo M; López-Soto A; Pietra G; Bugatti M; Munari E; Marconi M; Mingari MC; Vermi W; Moretta L; González S; Vitale M
Cancer Res; 2018 Jul; 78(14):3913-3925. PubMed ID: 29752261
[TBL] [Abstract][Full Text] [Related]
8. Proteomics approaches to understanding mitogen-activated protein kinase inhibitor resistance in melanoma.
Paulitschke V; Eichhoff O; Cheng PF; Levesque MP; Höller C
Curr Opin Oncol; 2016 Mar; 28(2):172-9. PubMed ID: 26742019
[TBL] [Abstract][Full Text] [Related]
9. Epithelial-to-mesenchymal-like transition events in melanoma.
Pedri D; Karras P; Landeloos E; Marine JC; Rambow F
FEBS J; 2022 Mar; 289(5):1352-1368. PubMed ID: 33999497
[TBL] [Abstract][Full Text] [Related]
10. Discoidin Domain Receptor 2 orchestrates melanoma resistance combining phenotype switching and proliferation.
Sala M; Allain N; Moreau M; Jabouille A; Henriet E; Abou-Hammoud A; Uguen A; Di-Tommaso S; Dourthe C; Raymond AA; Dupuy JW; Gerard E; Dugot-Senant N; Rousseau B; Merlio JP; Pham-Ledart A; Vergier B; Tartare-Deckert S; Moreau V; Saltel F
Oncogene; 2022 Apr; 41(18):2571-2586. PubMed ID: 35322197
[TBL] [Abstract][Full Text] [Related]
11. Proteomic identification of a marker signature for MAPKi resistance in melanoma.
Paulitschke V; Eichhoff O; Gerner C; Paulitschke P; Bileck A; Mohr T; Cheng PF; Leitner A; Guenova E; Saulite I; Freiberger SN; Irmisch A; Knapp B; Zila N; Chatziisaak TP; Stephan J; Mangana J; Kunstfeld R; Pehamberger H; Aebersold R; Dummer R; Levesque MP
EMBO J; 2019 Aug; 38(15):e95874. PubMed ID: 31267558
[TBL] [Abstract][Full Text] [Related]
12. Enabling Sensitive Phenotypic Profiling of Cancer-Derived Small Extracellular Vesicles Using Surface-Enhanced Raman Spectroscopy Nanotags.
Zhang W; Jiang L; Diefenbach RJ; Campbell DH; Walsh BJ; Packer NH; Wang Y
ACS Sens; 2020 Mar; 5(3):764-771. PubMed ID: 32134252
[TBL] [Abstract][Full Text] [Related]
13. Phenotype characterization of human melanoma cells resistant to dabrafenib.
Cordaro FG; De Presbiteris AL; Camerlingo R; Mozzillo N; Pirozzi G; Cavalcanti E; Manca A; Palmieri G; Cossu A; Ciliberto G; Ascierto PA; Travali S; Patriarca EJ; Caputo E
Oncol Rep; 2017 Nov; 38(5):2741-2751. PubMed ID: 29048639
[TBL] [Abstract][Full Text] [Related]
14. Mechanisms of resistance and predictive biomarkers of response to targeted therapies and immunotherapies in metastatic melanoma.
Mourah S; Louveau B; Dumaz N
Curr Opin Oncol; 2020 Mar; 32(2):91-97. PubMed ID: 31833956
[TBL] [Abstract][Full Text] [Related]
15. Phenotype switching in melanoma: implications for progression and therapy.
Li FZ; Dhillon AS; Anderson RL; McArthur G; Ferrao PT
Front Oncol; 2015; 5():31. PubMed ID: 25763355
[TBL] [Abstract][Full Text] [Related]
16. CD44 Facilitates Epithelial-to-Mesenchymal Transition Phenotypic Change at Acquisition of Resistance to EGFR Kinase Inhibitors in Lung Cancer.
Suda K; Murakami I; Yu H; Kim J; Tan AC; Mizuuchi H; Rozeboom L; Ellison K; Rivard CJ; Mitsudomi T; Hirsch FR
Mol Cancer Ther; 2018 Oct; 17(10):2257-2265. PubMed ID: 30049789
[TBL] [Abstract][Full Text] [Related]
17. Transcriptional signatures underlying dynamic phenotypic switching and novel disease biomarkers in a linear cellular model of melanoma progression.
Pessoa DO; Rius FE; Papaiz DD; Ayub ALP; Morais AS; de Souza CF; da Paixão VF; Setubal JC; Newton-Bishop J; Nsengimana J; Azevedo H; Reis EM; Jasiulionis MG
Neoplasia; 2021 Apr; 23(4):439-455. PubMed ID: 33845354
[TBL] [Abstract][Full Text] [Related]
18. Role of dual specificity phosphatases (DUSPs) in melanoma cellular plasticity and drug resistance.
Singh MK; Altameemi S; Lares M; Newton MA; Setaluri V
Sci Rep; 2022 Aug; 12(1):14395. PubMed ID: 35999349
[TBL] [Abstract][Full Text] [Related]
19. Extracellular vesicles from mast cells induce mesenchymal transition in airway epithelial cells.
Yin Y; Shelke GV; Lässer C; Brismar H; Lötvall J
Respir Res; 2020 May; 21(1):101. PubMed ID: 32357878
[TBL] [Abstract][Full Text] [Related]
20. Extracellular Vesicle-Packaged miR-195-5p Sensitizes Melanoma to Targeted Therapy with Kinase Inhibitors.
Santos NL; Bustos SO; Reis PP; Chammas R; Andrade LNS
Cells; 2023 May; 12(9):. PubMed ID: 37174717
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
